Defining the Role of Extended Half-Life Replacement Clotting Factors in the Modern Management of Hemophilia A is organized by PeerView Institute for Medical Education (PVI) and will be held from Feb 25, 2019 - Feb 24, 2020.

Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia A.

Credits:
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Description:
In this activity, experts in hematology explore the role of extended half-life replacement clotting factors for managing patients with hemophilia A.

Educational Objectives:
Upon completion of this activity, participants should be better able to:

• Assess the benefits and clinical shortcomings associated with conventional replacement factor VIII products for the management of hemophilia A
• Cite the latest clinical data with respect to efficacy, safety, and tolerability of extended half-life replacement factor VIII products for the treatment of hemophilia A
• Develop strategies to optimally integrate extended half-life replacement FVIII products into clinical practice

Additional details will be posted as soon as they are available.